Dr. Gottlieb on China's biotech strategy: China has become very adept at following U.S. discoveries

home system. I've got two of the three words. All right.Former FDA Commissioner Scott Gottlieb recently wrote an op ed in the Washington Post titled the FDA Should Copy China's Strategy to Speed Drug Discovery. He talks about how China is gaining ground in the United States in biotech, noting that its advantage is cost, not science. By cost, we mean cheaping out.Joining us right now is Doctor Scott Gottlieb. He's also a CNBC contributor, and he serves on the boards of both Illumina and Pfizer. And Scott, th ...